Candidate vaccines for immunotherapy in HIV.
In this short article we review the immunopathology of HIV infection and delineate the kinds of immune responses seen in acute infection and in long-term nonprogression that are understood to be necessary if the host is to maintain long-term control of the virus. In this context we discuss the potential promise of therapeutic vaccination in HIV infection.
Gotch
F M
FM
Department of Immunology, Imperial College School of Medicine, Chelsea and Westminster Hospital, London, UK. f.gotch@ic.ac.uk
Imami
N
N
Hardy
G
G
D016915:AIDS Vaccines / Q000276:immunology* / Q000627:therapeutic use*; D000208:Acute Disease; D019380:Anti-HIV Agents / Q000276:immunology / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D003131:Combined Modality Therapy; D016207:Cytokines / Q000187:drug effects / Q000276:immunology / Q000627:therapeutic use; D018450:Disease Progression; D016655:HIV Core Protein p24 / Q000276:immunology / Q000627:therapeutic use; D015658:HIV Infections / Q000276:immunology* / Q000628:therapy* / Q000821:virology; D006801:Humans; D007167:Immunotherapy / Q000379:methods* / Q000592:standards; D018579:Patient Selection; D013997:Time Factors; D016896:Treatment Outcome; D019562:Viral Load
D016915:AIDS Vaccines; D019380:Anti-HIV Agents; D016207:Cytokines; D016655:HIV Core Protein p24; C053473:VaxSyn HIV-1 (gp160) vaccine; C065031:p24-VLP vaccine; C105086:remune